Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.60 |
| ▸ | DNMT3L | Q9UJW3 | 5/20 | 0.60 |
| ▸ | DNMT3A | Q9Y6K1 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501270 | 0.87 | DNMT1 (0.75) | DNMT1DNMT3LDNMT3AMAPTCYP1A2 | |
| SCHEMBL3500154 | 0.86 | CYP1A2 (0.62) | DNMT1DNMT3LDNMT3AMAPTCYP1A2 | |
| SCHEMBL13312580 | 0.85 | DNMT1 (0.58) | DNMT1DNMT3LDNMT3AMAPTCYP1A2 | |
| SCHEMBL13963126 | 0.79 | CYP1A2 (0.57) | DNMT1DNMT3LDNMT3ACYP1A2CYP2D6 | |
| SCHEMBL12240925 | 0.78 | DNMT1 (0.75) | DNMT1DNMT3LDNMT3AMAPTCYP1A2 | |
| SCHEMBL12240493 | 0.78 | DNMT1 (0.75) | DNMT1DNMT3LDNMT3AMAPTCYP1A2 | |
| SCHEMBL13963095 | 0.78 | DNMT1 (0.75) | DNMT1DNMT3LDNMT3AMAPTCYP1A2 | |
| SCHEMBL3501609 | 0.78 | GPR68 (0.51) | MAPTRAB9ANPC1 | |
| SCHEMBL13963099 | 0.77 | ROCK1 (0.66) | DNMT1DNMT3LDNMT3AMAPTCYP1A2 | |
| SCHEMBL12240383 | 0.77 | TP53 (0.69) | DNMT1DNMT3LDNMT3AMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137566-A1 | Compounds and Methods Used to Treat Infectious Diseases | CYTOKINE PHARMASCIENCES, INC (US) | 2010-06-03 | — | — | US | disclosed |
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | BUKRINSKY MICHAEL I | 2006-01-19 | — | — | US | disclosed |
| US-6906076-B2 | Compounds and methods of use to treat infectious diseases | CYTOKINE PHARMASCIENCES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040053815-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2004-03-18 | — | — | US | disclosed |
| EP-0865434-B1 | COMPOUNDS AND THEIR USE TO TREAT INFECTIOUS DISEASES | PICOWER INST MED RES (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6649797-B2 | Contacting protein with a compound that is capable of stable reversible binding with basic amino acid residues of nuclear localization signal of protein for inactivating a nuclear localization signal of a protein | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2003-11-18 | — | — | US | disclosed |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2002-06-20 | — | — | US | disclosed |
| US-6297253-B1 | INACTIVATING A NUCLEAR LOCALIZATION SIGNAL OF A PROTEIN COMPRISING CONTACTING THE PROTEIN WITH AN ARYL CARBONYL COMPOUND THAT FORMS STABLE REVERSIBLE COVALENT INTERACTIONS WITH NEIGHBORING BASIC AMINO ACID RESIDUES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-10-02 | — | — | US | disclosed |
| US-5840893-A | TREATING MALARIA, HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0865434-A1 | COMPOUNDS AND METHODS OF USE TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-09-23 | — | — | EP | disclosed |
| EP-0865434-A4 | — | — | 1998-09-23 | — | — | EP | disclosed |
| WO-1998016515-A1 | COMPOUNDS AND METHODS TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5733932-A | VIRICIDES MARKING AND BLOCKING SPECIFIC VIRAL PROTEINS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-03-31 | — | — | US | disclosed |
| US-5703086-A | TREATMENT OF HIV INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-12-30 | — | — | US | disclosed |
| US-5620983-A | BLOCKING MOVEMENT OF VIRAL GENOME PARTICLES THROUGH NUCLEAR MEMBRANE IN TERMINALLY DIFFERENTIATED CELLS TO PREVENT VIRAL INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-04-15 | — | — | US | disclosed |
| US-5574040-A | DIALKANOYLPHENYLPYRIMIDINE DERIVATIVES | PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1996020932-A1 | COMPOUNDS AND METHODS OF USE TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | DNMT1 2539/4885DNMT3L 2834/4885DNMT3A 3537/4885 |
| US-20100137566-A1 | Compounds and Methods Used to Treat Infectious Diseases | KPNA1, NFATC1, MAVS | DNMT1 2519/4885DNMT3L 2991/4885DNMT3A 3582/4885 |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | DNMT1 2539/4885DNMT3L 2834/4885DNMT3A 3537/4885 |
| US-20040053815-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | DNMT1 2539/4885DNMT3L 2834/4885DNMT3A 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.